Researchers Evaluated NSAID Risks for Cancer Patients
A study presented in September 2026 analyzed potential toxicity risks among palliative care patients.
Updated on Sept. 24, 2026 in Cancer
Live Poll
Do you trust predictive risk models to guide your personal medical decisions?
Researchers from the University of California, San Diego, recently presented retrospective analyses regarding NSAID toxicity risks for cancer patients at the PAINWeek conference. The studies evaluated major toxicity probability in both inpatient and outpatient palliative care settings.
Why it matters
The research addresses a significant lack of high-quality evidence concerning the safety of NSAID use in cancer populations. By identifying predictive factors like hypertension, clinicians may better manage pain while minimizing medication-related harm.
Researchers observed 1-year major toxicity risks of 11.2% for inpatient NSAID users and 4.1% for certain outpatient groups. Common predictive factors identified across the cohorts included hypertension and concurrent statin use.
The players
University of California, San Diego
This is a public research university that oversaw the clinical research team conducting these palliative care studies.
Jacobs Medical Center
This facility served as the inpatient site for the retrospective analysis of NSAID toxicity.
The details
The inpatient study, conducted at Jacobs Medical Center, monitored 574 patients, while the outpatient cohort included 228 individuals. Both studies utilized predictive modeling applied to records from palliative care consultations to determine toxicity severity.
Timeline
Inpatient data collection occurred from January 2022 to July 2023.
Outpatient data collection occurred from January 2023 to March 2024.
Findings were presented at the PAINWeek conference on September 8-11, 2026.
The Big Picture
This study marks an expansion of the University of California, San Diego palliative care research program's focus on medication safety. It demonstrates an ongoing effort to bridge clinical gaps in pain management protocols for oncology patients.
Patients with cancer who use NSAIDs may experience different toxicity risks based on their status as inpatients or outpatients. Clinicians may use these predictive findings to better weigh the necessity of pain management against the individual risks posed by hypertension or statin use.
The takeaway
These findings underscore the importance of individualized risk assessment when prescribing pain medication to oncology patients. Patients are encouraged to discuss their complete medication history, including statin use and underlying conditions like hypertension, with their providers.
Further reading
For more on evolving standards in oncology care, visit the Cancer section.
Source note: This article includes information reported by Clinical Advisor.
Live Poll
Do you trust predictive risk models to guide your personal medical decisions?
